Regen BioPharma Inc (RGBP)

[cvinvestor]

Is 2015 a New Case for Hope?

Decided to go back and reread 2015 PRs to see if I could piece together a valid case for hope and that the buzz and buildup to divvy date does not end up the same as the RGBP spinoff (that was supposed to be above a dollar, remember?) And it is encouraging to see that price is sustaining and growing after last PR - could it be this it not another false alarm?

Here's about the best case scenario I can build that is not complete fantasy:
[First, everyone should read this article giving some personal background on Dr. Christine Ichim because I think she is now a major player in what is taking place, posted back in Dec by 1-eye-jack (interestingly enough): Why Dr Thomas Ichim and sister Dr. Christine Ichim are so motivated ].

Jan 8, 2015 PR mentions 2nd Generation of gene silencing drug candidate directed at NR2F6, a treatment that leads cancer cells to change into non cancerous cells: "The findings of novel candidate sequences to improve gene silencing of NR2F6 is a fundamental advancement in our work towards biologically treating cancer," said Dr. Thomas Ichim, Chief Scientific Officer. "Given that Regen BioPharma is already clinically developing gene-silencing therapeutics in its IND for dCellVax, we anticipate substantial synergy of these programs."

Jan 14, 2015 PR giving overview of 2015 priorities talks first about this new treatment candidate (not dCellVax or HemaX), then mentions dCellVax and says HemaXellerate protocols are still under review by FDA for conducting an additional GLP safety study.

Jan 22, 2015 PR - One week later we have the 8K filed to hire both Ichims (Thomas and Christine) with monthly salary and stock (even though RGBP doesn't have the cash). Ergo, I see another confirmation that NR2F6 is now the main focus since its small molecule inhibitors and such have proved effective in similar clinical treatments for a different cancer at success rates over 80% cfr notation in Jan 14th PR. And Christine is the person who has been working and developing this treatment. (Previously she was working on cancer cure for dogs under Entest, so to move her into RGBP and purchase her treatment patents is a clear new direction for RGBP.

Feb 9, 2015 8K tells us RGBP issues promissory Note for $50,000 (not a huge amount, but enough to cover new salaries for a couple months).

Feb 13, 2015 A few days later Todd Caven becomes CFO (whose background is supposed to be in securing funds / mergers).

Feb 17, 2015 Another 8K confirming the issuance of shares to all new hires.

Feb 24, 2015 PR to comment on Flexus buyout as validation of RGBP's own patents and treatments in development. Trying to generate interest of investors and money needed to develop - i.e. Todd Cavens job.

Feb 24, 2015 PR Piggy back PR stating issuance of dividend to shareholders of March 10 of Series A preferred (voting value and future dividend value)


So what to make of these many PRs in succession after our usual long periods of silence? Here are possible scenarios:

1. Worst case - annual bluff to drive up price at least for a few days if Koos and Company have a scam to make money by shorting it or somehow else where SEC does not see it. (Conspiracy theorists and basher bait)

2. Company has been rather stagnated and hoping new hires and people will help to start bringing the company forward. (No major news around the corner, just starting the process of regular updates to act like a real business)

3. RGBP is about to turn the corner with the new NR2F6 breakthrough and has had interest and guarantees of some kind of partnership to fund not only NR2F6, but advance dCellVax and HemaX as well.

4. BEST case scenario: RGBP has finally received word that HemaX protocol for safety trials will be approved, dCellVax will also get Green Light and the development of NR2F6 is so positive, that they are positioning themselves against an outright takeover and setting structure for an advantageous partnership once the news of these 3 developments all hit at once.


I don't know which is the more probable, but I think the recent actions are more focused on NR2F6 holding the brightest future of development and buyout possibilities than either HemaX or dCellVax at this time.

AIMO

Pax.

Now I shall return to my silence and wait for the play to unfold, at least now with a little bit more hope that this time it will be real and successful and not another trick play.